241 related articles for article (PubMed ID: 23725286)
1. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
2. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
3. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
4. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
6. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
7. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?
Meiners PM; Vissink A; Kallenberg CG; Kroese FG; Bootsma H
Expert Opin Biol Ther; 2011 Oct; 11(10):1381-94. PubMed ID: 21819314
[TBL] [Abstract][Full Text] [Related]
8. Emerging biotherapies for Sjögren's syndrome.
Tobón GJ; Saraux A; Pers JO; Youinou P
Expert Opin Emerg Drugs; 2010 Jun; 15(2):269-82. PubMed ID: 20384543
[TBL] [Abstract][Full Text] [Related]
9. Anti-B cell antibody therapies for inflammatory rheumatic diseases.
Faurschou M; Jayne DR
Annu Rev Med; 2014; 65():263-78. PubMed ID: 24160940
[TBL] [Abstract][Full Text] [Related]
10. B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.
Hayakawa I; Tedder TF; Zhuang Y
Immunology; 2007 Sep; 122(1):73-9. PubMed ID: 17472721
[TBL] [Abstract][Full Text] [Related]
11. [B lymphocytes in Sjögren's syndrome].
Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 antibody in primary Sjögren's syndrome management.
Chen S; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
[TBL] [Abstract][Full Text] [Related]
13. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
15. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
Saraux A
Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
[TBL] [Abstract][Full Text] [Related]
16. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome.
Coca A; Sanz I
Curr Opin Rheumatol; 2012 Sep; 24(5):451-6. PubMed ID: 22871954
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
18. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
19. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.
Vossenkämper A; Lutalo PM; Spencer J
Clin Exp Immunol; 2012 Jan; 167(1):7-14. PubMed ID: 22132879
[TBL] [Abstract][Full Text] [Related]
20. The complexity of Sjögren's syndrome: novel aspects on pathogenesis.
Jonsson R; Vogelsang P; Volchenkov R; Espinosa A; Wahren-Herlenius M; Appel S
Immunol Lett; 2011 Dec; 141(1):1-9. PubMed ID: 21777618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
